← Back to screener

BIOCRYST PHARMACEUTICALS INC BCRX

Rank #1876 · Nasdaq · $2.2B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
39.9
P/E
-9.5
P/B
-7.31
ROE
76.9%
Op. Margin
-31.3%
Debt Ratio
-328%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -9.5x, P/B -7.31x. Ranks in the top 92% of the universe.

Profitability ★★★☆☆
Average

ROE 76.9%. Ranks in the top 45% of the universe.

Safety ★★★★★
Excellent

Debt ratio -328%. Ranks in the top 4% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★☆
Excellent

Revenue growth of 22.4% year over year. Ranks in the top 16% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B–136
2012$0.1B$-0.0B$-0.0B$0.1B-55.1-5
2013$0.0B$-0.0B$-0.1B$0.1B-252.4-12
2014$0.0B$-0.0B$-0.0B$0.0B-128.9230
2015$0.0B$-0.0B$-0.0B$-0.0B-177.2-30248
2016$0.0B$-0.0B$-0.0B$-0.0B-336.4-10967
2017$0.0B$-0.0B$-0.0B$0.1B-81.719
2018$0.0B$-0.0B$-0.1B$0.0B-184.4274
2019$0.0B$-0.1B$-0.1B$0.0B-227.99206
2020$0.0B$-0.1B$-0.1B$0.1B-456.2109
2021$0.0B$-0.1B$-0.1B$0.0B-203.7580
2022$0.0B$-0.2B$-0.2B$0.0B-981.11438
2023$0.2B$-0.2B$-0.2B$-0.0B-113.1-2955
2024$0.3B$-0.1B$-0.2B$-0.1B-54.8-909
2025$0.3B$-0.1B$-0.2B$-0.3B-31.3-328

← See the full screener